Susceptibility of Mexican Brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 9, 2004, Pages 636-638

  López Merino, Ahidé ^a   Contreras Rodríguez, Araceli ^a   Migranas Ortiz, Roberto ^a   Orrantia Gradín, Rubén ^b   Hernández Oliva, Gerardo M ^b   Gutiérrez Rubio, Arturo Torres Y ^b   Cardeñosa, Oscar ^b  

^a INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^b Bayer Company   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; BRUCELLA; BRUCELLOSIS; CONTROLLED STUDY; DAIRY PRODUCT; DOMESTIC ANIMAL; IN VITRO STUDY; MEXICO; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE; WILDLIFE;

EID: 4644345011     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Fact sheet N173. Geneva: World Health Organization, 1997.
2. Mikolon AB, Gardner IA, Hernandez de Anda J, Hietala SK. Risk factors for brucellosis seropositivity of goats in the Mexicalli Valley of Baja California, Mexico. Prev Vet Med 1998; 37: 185-95.
3. Dirección General de Epidemiología. Información epidemiológica de morbilidad 2003. Secretaria de Salud, Mexico. www.dgepi.salud.gob.mx
4. Secretaría de Salud. Norma Oficial Mexicana para la prevención y control de la brucelosis en el hombre, en el primer nivel de atención. Mexico City: Secretaría de Salud, NOM-022-SSA2-1994, 1995.
5. Young EJ. Treatment of brucellosis in humans. In: Young EJ, Corbel MJ, eds. Brucellosis: clinical and laboratory aspects. Boca Raton: CRC Press; 1989. p. 127-41.
6. Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira, J, Miravitlles MR. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study. Ann Intern Med 1992; 117: 25-30.
7. Bosch J, Liñares J, López de Goicochea MJ, Ariza J, Cisnal MC, Martin R. In vitro activity of ciprofloxacin, ceftriaxone and 5 other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother 1986; 17: 459-61.
8. García-Rodríguez JA, García-Sánchez JE, Trujillano I, García-García MI. Susceptibilities of Brucella melitensis to clinafloxacin and 4 other new fluoroquinolones. Antimicrob Agents Chemother 1995; 35: 1925-7.
9. Kahn MY, Dizon M, Kiel FW. Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin and other selected antimicrobial agents against Brucella melitensis. Antimicrob Agents Chemother 1989; 33: 1409-10.
10. Kato T, Novi S, Nushi A, Dedja S. Ciprofloxacin plus docycycline vs rifampicin plus doxycycline in the treatment of acute brucellosis. Med Maladies Infect 1996; 26: 587-9.
11. Lang R, Rubinstein E. Quinolones for the treatment of brucellosis. J Antimicrob Chemother 1992; 29: 357-63.
12. Walters JD, Zhang F, Nakkula RJ. Mechanism of fluoroquinolone transport by human neutrophils. Antimicrob Agents Chemother 1999; 43: 2710-5.
13. Pascual A, García I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999; 43: 12-5.
14. Steers SE, Foltz E, Graves SB. An inocula replicating apparatus for routine testing of bacterial susceptibility Antibiotics Chemother 1959; 9: 387-411.
15. Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases, 5th edn. Philadelpia: Churchill Livingstone; 2000. p. 2386-90.
16. Easmon CSF, Crane JP, Blowers A. Effect of ciprofloxacin on intracellular organisms: in vitro and in vivo studies. J Antimicrob Chemother 1986; 18(Suppl D): 43-8.
17. Kocagöz S, Akova M, Altun B, Gür D, Hasçelik G. In vitro activities of new quinolones against Brucella melitensis isolated in a tertiary-care hospital in Turkey. Clin Microbiol Infect 2002; 8: 240-2.
18. Akova M, Gür D, Livermore DM, Kocagöz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43: 1298-300.
19. García-Rodríguez JA, García-Sánchez JE, Trujillano I. Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 1991; 35: 756-9.
20. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Çolpan A, Erbay A. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003; 35: 337-8.
21. Trujillano-Martín I, García-Sánchez E, Montes-Martínez I, Fresnadillo MJ, García-Sánchez JE, García-Rodríguez JA. In vitro activities of six fluoroquinolones against Brucella melitensis. Antimicrob Agents Chemother 1999; 43: 194-5.
22. Carrillo C, Gotuzzo E, Adachi J, Tolmos J. Sensibilidad antimicrobiana in vitro de cepas de Brucella melitensis aisladas en un área endémica (Lima, Perú). Rev Esp Quimioter 1993; 6: 309-13.
23. Almuneef M, Memish ZA, Al Shaalan M, Al Banyan E, Al-Alola S, Balkhy HH. Brucella melitensis bacteremia in children: review of 62 cases. J Chemother 2003; 15: 76-80.
24. Kinsara A, Al-Mowallad A, Osoba AO. Increasing resistance of Brucella to co-trimoxazole. Antimicrob Agents Chemother 1999; 43: 1531.